Baird served as a co-manager on this transaction.
AboutAuspex Pharmaceuticals, Inc. (“Auspex” or the “Company”) (NASDAQ: ASPX) recently completed a follow-on offering of 4,600,000 shares of common stock at a price of $56.50 per share, generating gross proceeds of approximately $203.4 million. Auspex sold 3,600,000 shares of common stock and certain existing stockholders of Auspex sold 1,000,000 shares of common stock. The Company intends to use the net proceeds from the offering to fund building the commercial organization for, and commercial launch of, SD-809, if approved, for the potential treatment of chorea associated with Huntington’s disease; for research and development; and for working capital and other general purposes.
Auspex is a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders and other rare diseases, including orphan diseases, which are rare diseases that affect fewer than 200,000 people in the United States. The Company’s pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, and tardive dyskinesia and Tourette syndrome, subsets of either of which may be deemed to be orphan diseases, as well as other orphan indications. Auspex is headquartered in La Jolla, California.
For additional information about this transaction, please contact:
- January 2015
- Auspex Pharmaceuticals, Inc.
- Target Location
- North America